Epitalon and Epithalon spellings can lead buyers to several similarly named listings. Spelling alone is a poor acceptance criterion. A research-material request should connect the intended name to the defined residue sequence and supplied form, then ask which documents address the actual offered sample rather than the spelling on a webpage.
Anchor the request to AEDG
The PubChem Epitalon record represents Ala-Glu-Asp-Gly, or AEDG, with H-Ala-Glu-Asp-Gly-OH notation. The record also includes Epithalon among its names. Use this specific structural reference when describing the intended material. Do not infer that every similarly spelled extract, mixture or commercial description has the same composition simply because a database contains an overlapping name.
Separate search aliases from accepted identity
Keep the spelling used on the catalog page and the reviewed sequence together. A synonym helps retrieve a record; it should not override a conflicting structure or unclear material description. If the supplier replies with a different name, ask whether only the label changed or whether the offered material changed. The worksheet records both, preventing an administrative spelling correction from concealing an unresolved chemical-identity difference.
| Entry | What to retain | Question to resolve |
|---|---|---|
| Catalog spelling | Exact displayed name and URL | Same intended material? |
| Reference identity | AEDG / Ala–Glu–Asp–Gly | Offered sequence confirmation |
| Termini | H–AEDG–OH in the cited record | Actual terminal requirements |
| Related description | Structure, mixture or extract explicitly named | No assumed synonym equivalence |
| Order evidence | Form, quantity basis and sample records | Batch-specific review |
Check residue order and linkage description
AEDG is an ordered peptide description, not a list of four amino acids that can be rearranged. Request the offered structural notation, termini and stereochemistry. If a modified linkage or terminal cap is proposed, record it explicitly and obtain review. Do not assume an ordinary sequence abbreviation describes every possible related structure. A database reference identifies its represented molecule; the buyer still needs supplier confirmation for the offered material.
Keep form and quantity questions independent
Ask for the actual chemical-form statement and declared additional constituents. Then record the amount basis, container count and report scope. A four-residue sequence does not imply a fixed fraction of peptide in supplied solids. Do not calculate content from a photograph or treat chromatography area percentage as a direct mass measurement. If a measured amount is supplied, retain its method, sample reference and reporting basis with the quantity record.
Use the identity card for future orders
Retain the accepted sequence and terminal description alongside the alias mapping and supplier response. For a repeat request, ask whether that baseline remains unchanged and review the allocated lot’s evidence separately. This makes the record reusable without treating an old report as proof for a new batch. Published biological discussions are not part of this identity acceptance card, and the material’s name does not establish clinical approval or suitability for human use.
Before closing this review
- Alias mapping does not override structure.
- Residues retain their order.
- Related materials are not silently merged.
- Repeat orders recheck batch-specific evidence.
Continue with review the relevant catalog record; prepare a precise material inquiry. Save the relevant product or guide link alongside the written response so another reviewer can reconstruct the decision.
Editorial scope: research-material procurement and document review. Not medical guidance, dosing instructions or a claim of suitability for human use. Requirements and availability must be confirmed for the quoted material.
